Experimental stroke drug RNS60 passes early safety check in small trial

NCT ID NCT04693715

Completed Disease control Sponsor: Revalesio Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tested the safety of an experimental drug called RNS60 in 83 people having a severe stroke caused by a large blood clot. Participants received either RNS60 or a placebo as a 48-hour infusion, starting within 30 minutes of consent. The main goal was to check for serious side effects and survival at 90 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RNS60 injection solution
What this could lead to: If safe and effective, RNS60 could improve recovery after severe stroke by protecting brain cells during treatment.
What could go wrong: This is an early Phase 2 safety trial with only 83 participants, so results may not confirm benefit. The drug is still experimental and not yet proven to work.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE DUE TO LARGE VESSEL OCCLUSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke large artery stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

STROKE, ISCHEMIC

Contacts and locations

Locations

Chattanooga Center for Neurologic Research

Chattanooga, Tennessee, 37404, United States
Houston Methodist Hospital

Houston, Texas, 77030, United States
Northwestern University

Chicago, Illinois, 60611, United States
Oregon Health & Science University

Portland, Oregon, 97239, United States
Rhode Island Hospital

Providence, Rhode Island, 02903, United States
The Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
Thomas Jefferson University

Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.